NEI Research News

Researchers used artificial intelligence (AI) to evaluate stem cell-derived “patches” of retinal pigment epithelium (RPE) tissue for implanting into the eyes of patients with age-related macular degeneration (AMD), a leading cause of blindness.

Using a canine model of the vision disorder Leber congenital amaurosis, Penn researchers found that photoreceptor cells continue to deteriorate after treatment if it is given too late.

Retinitis pigmentosa (RP) is a common hereditary eye disorder that leads to the gradual deterioration of rod cells causing reduced peripheral vision and night vision. Subsequent loss of cone photoreceptors cause the loss of high-resolution daylight...

The Knights Templar Eye Foundation has awarded two NEI scientists grants to research inherited retinal degenerations, diseases that can cause blindness in early childhood.

A new study shows that the complement system, part of the innate immune system, plays a protective role to slow retinal degeneration in a mouse model of retinitis pigmentosa, an inherited eye disease.

Johns Hopkins Medicine researchers report they have created a method of mapping how the central nervous system develops by tracking the genes expressed in cells.

Johns Hopkins Medicine scientists say that new experiments with mouse eye tissues strongly suggest that a longstanding “textbook concept” about the way a mammal’s retina processes light needs a rewrite.

A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the central nervous system—including the retina of the eye—serve as “gatekeepers,” or biosensors and facilitators, of neuroinflammation...

Eating a calcium-rich diet or taking calcium supplements does not appear to increase the risk of age-related macular degeneration (AMD), according to the findings of a study by scientists at the National Eye Institute (NEI).

A new therapy developed by researchers at the University of California, Berkeley, could help prolong useful vision and delay total blindness for people with retinitis pigmentosa.